The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study.
Ralf Hofheinz
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Wilfried Grothe
No relevant relationships to disclose
Dirk Tummes
Research Funding - Roche
Manfred Kindler
No relevant relationships to disclose
Volker Petersen
No relevant relationships to disclose
Stefanie Boszeit-Luft
No relevant relationships to disclose
Joerg Seraphin
No relevant relationships to disclose
Axel Hinke
No relevant relationships to disclose
Dirk Arnold
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche